ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
January 15, 2024 03:00 ET
|
ExeVir Bio
GHENT, Belgium, Jan. 15, 2024 (GLOBE NEWSWIRE) -- ExeVir Bio, a biotech company developing robust heavy chain-only antibody therapies for broad protection against infectious diseases, today...
ExeVir Bio Awarded EUR 1.6m Grant for Dengue Research
June 28, 2023 03:09 ET
|
ExeVir Bio
Dengue is a mosquito-borne viral infection listed by WHO as top 10 threat for global health The government grant is awarded by Flanders Innovation & Entrepreneurship (VLAIO) GHENT, Belgium, June...
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19
March 13, 2023 05:00 ET
|
ExeVir Bio
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spikeFocus on protecting...
ExeVir Bio ontvangt 25 miljoen euro financiering met durfkapitaal van de Europese Investeringsbank
January 09, 2023 02:00 ET
|
ExeVir Bio
Financiering voor de verdere wetenschappelijke ontwikkeling van innovatieve COVID-19-behandelingen met nanobody’s voor de bescherming van hoog risicogroepen met verminderde immuniteit Het bedrijf...
ExeVir Bio contracte un prêt d’amorçage-investissement de 25 millions d’euros auprès de la Banque européenne d’investissement
January 09, 2023 02:00 ET
|
ExeVir Bio
Financer le développement scientifique de traitements innovants contre le COVID-19 basés sur des nanocorps, visant à protéger des personnes immunodéprimées à haut risque L’entreprise développe des...
ExeVir Bio secures EUR 25 million venture debt financing from the European Investment Bank
January 09, 2023 02:00 ET
|
ExeVir Bio
Financing to advance the scientific development of innovative COVID-19 nanobody treatments focused on protecting high-risk immunocompromised individuals Company developing highly potent antibodies...